STOCK TITAN
  1. Home
  2. News
  3. EOLS

Evolus Inc - EOLS STOCK NEWS

Welcome to our dedicated news page for Evolus (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evolus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evolus's position in the market.

News
Evolus to Report First Quarter Financial Results on May 7, 2024
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) will report its first quarter 2024 financial results on May 7, 2024. The company will host a conference call and webcast to discuss the results. Investors can participate in the call and access the webcast through the Evolus website. A question-and-answer session will follow management's remarks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
conferences earnings
-
News
Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®
Rhea-AI Summary
Evolus, Inc. (NASDAQ: EOLS) announces the publication of safety and duration data from a Phase 2 study for the 'extra-strength' 40U formulation of Jeuveau® in treating moderate to severe glabellar lines. The study showed a duration effect of 26 weeks based on improvement in Glabellar Line Scale (GLS) and Global Aesthetic Improvement Scale, with a focus on safety and efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
clinical trial
-
News
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Evolus, Inc. (EOLS) reports the grant of stock options and restricted stock units to new non-executive employees under the 2023 Inducement Incentive Plan. The awards are material to the new employees entering into employment with Evolus, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $13.26 per share and a 10-year term, vesting over 4 years, while the RSUs vest 25% annually. The grants are subject to specific conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none
News
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Evolus, Inc. (EOLS) will participate in the 23rd Annual Needham Virtual Healthcare Conference on April 9th, 2024. The management team will present at 9:30 AM ET, discussing the company's performance beauty focus. Investors can access the fireside chat on Evolus' Investor Relations page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
conferences
-
News
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
Rhea-AI Summary
Evolus, Inc. (EOLS) announces the pricing of its underwritten offering of 3,554,000 shares of common stock at $14.07 per share, aiming to raise approximately $50.0 million. The offering includes an option for underwriters to purchase additional shares. The offering is set to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
offering
-
News
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Evolus, Inc. (EOLS) granted non-qualified stock options and restricted stock units to 8 new non-executive employees. The awards were approved under the 2023 Inducement Incentive Plan, with an exercise price of $14.79 per share. The stock options have a 10-year term and vest over 4 years, while the RSUs vest 25% annually. The awards are subject to employment conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
News
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
Rhea-AI Summary
Evolus, Inc. (EOLS) reported positive financial results for Q4 2023 and full year 2023, with $0.8M cash generated from operating activities, a $3.7M non-GAAP operating loss for Q4, and $163.9M operating expenses. The company achieved a global net revenue record of $61.0M for Q4 and $202.1M for full year 2023, showing significant growth. Evolus updated its mid-term guidance, aiming for profitability in Q4 2024 and full year 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.87%
Tags
earnings
-
News
Evolus Announces Results from European Head-to-Head Filler Trial
Rhea-AI Summary
Evolus, Inc. (EOLS) announces statistical superiority of Evolysse™/Estyme® Lift dermal filler over Restylane-L in improving nasolabial fold severity. The European Lift study met the primary endpoint of non-inferiority. The filler line will be launched globally in 2025, branded as Evolysse™ in the US and Estyme® in the UK and Europe. The study demonstrated statistical superiority of Evolysse™/Estyme® Lift at 3 and 6 months, positioning it as a versatile and high-volume filler. Safety profiles were similar with no serious adverse events reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
News
Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences
Rhea-AI Summary
Evolus, Inc. (EOLS) announces participation in upcoming investor conferences in March 2024. Management team to present at Leerink Partners Global Biopharma Conference and Barclays Global Healthcare Conference. Webcast available on Evolus website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
conferences
News
Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024
Rhea-AI Summary
Evolus, Inc. (EOLS) announces the reporting of its fourth quarter and year-end 2023 financial results along with a business update on March 7, 2024. The company will host a conference call and live webcast to discuss the results, followed by a Q&A session.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
conferences
Stock EOLS logo
Evolus Inc

Nasdaq:EOLS

EOLS Rankings

#2684 Ranked by Market Cap
#2678 Ranked by Stock Gains
N/A Ranked by Dividends

EOLS Stock Data

743.51M
38.80M
13.05%
77.11%
7.56%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Newport Beach

About EOLS

evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.